U.S. Department of Veterans Affairs ceases use of bevacizumab for wet AMD while it investigates reports of increased risk of infection

Source: Reuters Health News
Area: News
According to a Reuters report, the U.S. Department of Veterans Affairs has stopped using bevacizumab to treat wet age-related macular degeneration while it investigates reports of increased risk of infection. Once the investigation is complete, it will reassess how bevacizumab and similar therapies may be made available for ophthalmological use and will issue further guidance. In August, the Florida Department of Health notified the FDA of Streptococcus endophthalmitis infections in three clinics following intraocular injections of repackaged bevacizumab.

Full Story →